Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (ab277512)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Human monoclonal [CV1] to SARS-CoV-2 Spike Ectodomain
- Suitable for: Indirect ELISA
Overview
-
Product name
Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1]
See all SARS-CoV-2 Spike Ectodomain primary antibodies -
Description
Human monoclonal [CV1] to SARS-CoV-2 Spike Ectodomain -
Host species
Human -
Tested applications
Suitable for: Indirect ELISAmore details -
Immunogen
Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.
-
General notes
CV1 antibody cross-reacts with SARS-CoV-2 Spike Ectodomain (including S1 domain), but not with SARS-CoV-2 Spike RBD. CV1 does not demonstrate significant neutralising ability in in-direct ELISA, measuring competitive binding of CV1 to SARS-CoV-2 Spike RBD in the presence of human ACE2
Please note: This antibody was first isolated as an IgG1 lambda subclass. During the cloning process for the recombinant product, this was converted to an IgG1 kappa subclass, although the light chain variable region is still of the lambda subclass.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Proclin 300
Constituent: 99% PBS -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Monoclonal -
Clone number
CV1 -
Isotype
IgG1 -
Light chain type
lambda -
Research areas
Images
-
Indirect ELISA showing ab277512 (CV1) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect ELISA showing ab277512 (CV1) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect competition ELISA showing competitive binding of ab277512 (CV1) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect competition ELISA showing competitive binding of ab277512 (CV1) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-